When using PD-1/PD-L1 inhibitors, the PD-L1 molecule on β cells can’t bind to PD-1 on autoreactive T cells, while the inflammation-stimulated autoreactive T cells are over-activated, greatly promoting the progression of diabetes. This evidence concerns the gene CD274 and diabetes mellitus.